Substituted bis-acridines and related compounds as ccr5 receptor ligands, anti-inflammatory agents and anti-viral agents
CA 2276525 A1 · Owner: Smithkline Beecham Corporation · Inventors: Bondinell, William E.; Ku, Thomas Wen Fu; Reader, Valerie A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to substituted bis-acridines and related compounds which are ligands, in particular, antagonists of the CCR5 receptor. In , addition, this invention relates to the treatment and prevention of disease states mediated by CCR5, including, but not limited to asthma and atopic , disorders (for example atopic dermatitis and allergies), rheumatoid arthritis, atherosclerosis, psoriasis, autoimmune diseases such as multiple sclerosis, and inflammatory bowel disease all in mammals, by the use of , substituted bis-acridines and related compounds which are CCR5 receptor antagonists. Also, since CCR5 is a co-receptor for the entry of HIV into cells, selective receptor …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 8, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 8, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 8, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.